RxDoctor Payments Data

Binna Chokshi, MD

Interventional Cardiology · Mansfield, TXNPI 1558771667

Payments from drug & device makers

$7,604in general payments, 2019–2025

Across 139 payments — averaging $54.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Philips North America LLC$2K
  • W. L. Gore & Associates, Inc.$1K
  • Abiomed$553
  • Boston Scientific$389
  • Abbott$349
  • plus $2K from 23 others

What the payments were for

  • Travel & lodging$2,86038%
  • Food & beverage$4,64461%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,604 in reported general payments places this provider in the 35th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$539,403
Medicare patients
1,074
Services billed
5,844

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban254$340,694
EntrestoSacubitril/Valsartan57$69,467
XareltoRivaroxaban52$68,764
Repatha SureclickEvolocumab18$27,375
BrilintaTicagrelor13$16,701
Dofetilide16$8,147
Atorvastatin Calcium347$3,616
Ranolazine ErRanolazine24$3,095
Ezetimibe165$2,667
Metoprolol Succinate237$2,664
ClopidogrelClopidogrel Bisulfate200$2,486
Rosuvastatin Calcium169$2,121
Losartan Potassium107$1,289
Metoprolol Tartrate189$1,109
Carvedilol71$505

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$340,694254 claims
NovartisEntresto$112$69,46757 claims
Johnson & JohnsonXarelto$55$68,76452 claims
AstraZenecaBrilinta$128$16,70113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Mansfield

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →